Channel Therapeutics Statistics Share Statistics Channel Therapeutics has 6.6M
shares outstanding. The number of shares has increased by -15.48%
in one year.
Shares Outstanding 6.6M Shares Change (YoY) -15.48% Shares Change (QoQ) -0.04% Owned by Institutions (%) n/a Shares Floating 2.56M Failed to Deliver (FTD) Shares 1,364 FTD / Avg. Volume 1.23%
Short Selling Information The latest short interest is 114.77K, so 0% of the outstanding
shares have been sold short.
Short Interest 114.77K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -4.49 and the forward
PE ratio is null.
Channel Therapeutics's PEG ratio is
-0.38.
PE Ratio -4.49 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio -13.17 P/FCF Ratio -6.17 PEG Ratio -0.38
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Channel Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.34,
with a Debt / Equity ratio of -0.81.
Current Ratio 0.34 Quick Ratio 0.34 Debt / Equity -0.81 Debt / EBITDA -0.29 Debt / FCF -0.38 Interest Coverage 9.63
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.99M Employee Count 4 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -81.61% in the
last 52 weeks. The beta is 3.29, so Channel Therapeutics's
price volatility has been higher than the market average.
Beta 3.29 52-Week Price Change -81.61% 50-Day Moving Average 14.67 200-Day Moving Average 12.73 Relative Strength Index (RSI) 57.88 Average Volume (20 Days) 111,305
Income Statement
Revenue n/a Gross Profit n/a Operating Income -7.57M Net Income -7.96M EBITDA -7.57M EBIT -8.74M Earnings Per Share (EPS) -1.43
Full Income Statement Balance Sheet The company has 513.44K in cash and 2.19M in
debt, giving a net cash position of -1.67M.
Cash & Cash Equivalents 513.44K Total Debt 2.19M Net Cash -1.67M Retained Earnings -21.47M Total Assets 911.18K Working Capital -4.2M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -5.79M
and capital expenditures 0, giving a free cash flow of -5.79M.
Operating Cash Flow -5.79M Capital Expenditures n/a Free Cash Flow -5.79M FCF Per Share -1.04
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CHRO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for CHRO.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 2, 2025. It was a
backward
split with a ratio of 1:10.
Last Split Date Jul 2, 2025 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -73.24 Piotroski F-Score 1
